Compare HAFC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | REPL |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.9M | 781.3M |
| IPO Year | 1996 | 2018 |
| Metric | HAFC | REPL |
|---|---|---|
| Price | $25.03 | $7.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $28.50 | $12.00 |
| AVG Volume (30 Days) | 262.2K | ★ 1.5M |
| Earning Date | 01-27-2026 | 02-06-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ 22.44 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $255,726,000.00 | N/A |
| Revenue This Year | $19.61 | N/A |
| Revenue Next Year | $11.05 | N/A |
| P/E Ratio | $11.34 | ★ N/A |
| Revenue Growth | ★ 11.21 | N/A |
| 52 Week Low | $19.25 | $2.68 |
| 52 Week High | $30.20 | $14.80 |
| Indicator | HAFC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 30.19 | 36.15 |
| Support Level | $28.02 | $7.39 |
| Resistance Level | $30.20 | $7.80 |
| Average True Range (ATR) | 0.96 | 0.48 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 9.45 | 28.40 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.